Universität zu Köln

Thelen, Philipp ORCID: 0000-0001-5073-8829, Henriksen, Anne Santerre, Longshaw, Christopher ORCID: 0000-0002-5586-7256, Yamano, Yoshinori, Caldwell, Ben and Hamprecht, Axel (2022). In vitro activity of cefiderocol against Gram-negative bacterial pathogens in Germany. J. Glob. Antimicrob. Resist., 28. S. 12 - 18. OXFORD: ELSEVIER SCI LTD. ISSN 2213-7173

Full text not available from this repository.

Abstract

Objectives: Widespread antimicrobial resistance in Gram-negative bacteria (GNB), particularly carbapenem resistance, represents a major clinical challenge. Cefiderocol is a novel siderophore cephalosporin active against all carbapenemase classes. Methods: We evaluated the in vitro activity of cefiderocol and other antibacterial agents (ceftazidime/avibactam, ceftolozane/tazobactam, colistin and meropenem) against GNB isolates collected in Germany (2013-2018) as part of two multinational studies. Antimicrobial susceptibility testing was performed by broth microdilution. Minimum inhibitory concentrations were interpreted according to EUCAST breakpoints. Results: Cefiderocol had high activity against GNB isolates (N = 2298), encompassing both Enterobacterales (n = 1562) and non-fermenter species (n = 736), and maintained high activity against carbapenem-resistant strains (n = 211). The activity of cefiderocol against Enterobacterales was equivalent to that of ceftazidime/avibactam and colistin, while ceftolozane/tazobactam was somewhat less active. Against non-fermenter species, cefiderocol displayed equivalent activity to colistin; both of these agents were more active than ceftazidime/avibactam and ceftolozane/tazobactam. Colistin had similar activity to cefiderocol against the majority of species. These patterns of activity were echoed in carbapenemresistant isolates. The high activity of cefiderocol was independent of infection site, whereas other antibacterial agents demonstrated slightly lower activity against isolates causing pneumonia compared with those from other key infection sites. Conclusion: Cefiderocol exhibited consistently high in vitro activity against a variety of GNB isolates collected in Germany, including resistant phenotypes, across multiple infection sites. These data suggest that cefiderocol is an effective choice of antibacterial agent in patients with GNB infection, regardless of species and resistance phenotype to other agents. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Thelen, Philipp UNSPECIFIED orcid.org/0000-0001-5073-8829 UNSPECIFIED Henriksen, Anne Santerre UNSPECIFIED UNSPECIFIED UNSPECIFIED Longshaw, Christopher UNSPECIFIED orcid.org/0000-0002-5586-7256 UNSPECIFIED Yamano, Yoshinori UNSPECIFIED UNSPECIFIED UNSPECIFIED Caldwell, Ben UNSPECIFIED UNSPECIFIED UNSPECIFIED Hamprecht, Axel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-680430
DOI:	10.1016/j.jgar.2021.10.029
Journal or Publication Title:	J. Glob. Antimicrob. Resist.
Volume:	28
Page Range:	S. 12 - 18
Date:	2022
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	2213-7173
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INFECTIONS Multiple languages Infectious Diseases; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/68043